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Objectives: In 2006, Conditional Marketing Authorisation (MA) was implemented 
by the European Medicines Agency (EMA) to ensure early access to innovative medi-
cations for patients in Europe. The objective of this study is to compare the health 
technology assessment (HTA) process in France, England, and Germany for medi-
cines having received a conditional approval over the past 9 years MethOds: The 
present study concerned all medicines having been approved with a conditional 
MA. The HTA assessments performed by three national bodies, IQWiG, NICE and 
HAS, were compared for these products. Results: Of the 19 medicines for which 
a conditional MA was requested, 17 have received an approval of this type. Three 
of these approved medicines have not yet been assessed by any of the three HTA 
bodies, or are currently undergoing assessment. Four medicines have undergone 
HTA assessment by all three agencies. An additional 9 medicines have been assessed 
in two of the three countries (4 by both HAS and NICE and 5 by both HAS and 
IQWiG). Whereas all products assessed by HAS received a favourable opinion for 
reimbursement, NICE and IQWiG are more restrictive in their recommendations. 
Indeed, only 1/8 medicines assessed by NICE received a favourable recommendation 
and 5/ 9 by IQWiG. Of note, a specific regulatory framework has been implemented in 
Germany by which IQWiG considers all orphan products approved by EMA to provide 
an added medical benefit. This disposition concerned 4 of the 5 products having 
received a favourable opinion in Germany. cOnclusiOns: The HTA assessments 
by HAS, IQWiG and NICE of medicines having received a conditional approval are 
heterogeneous and lead to differing reimbursement statuses. Different criteria are 
taken into consideration, including the relevance of the comparator, the clinical 
trial design and endpoints as well as the relevant target population and health 
economic assessment.
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Objectives: In 2014 the Catalan Health Service (CatSalut) published a guide (GAEIP) 
which describes the methodology for the economic evaluation of medicines in 
Catalonia. Now the objective is to design the operational aspects to introduce both 
the economic evaluations (EE) and budget impact analyses (BIA) of medicines in the 
three Health Technology Assessment (HTA) programmes of CatSalut. MethOds: 
The Commission for Economic Evaluation and Budget Impact (CAEIP) of CatSalut 
led the project that: 1) reviewed the processes undertaken by other countries that 
use EE/BIA of medicines; 2) ran focus groups with representatives of each of the 
three HTA programmes: primary and community care (PHF-APC), hospital medicines 
administered in ambulatory care (PHF-MHDA), and orphan medicines (PASFTAC); 
3) validated the proposal through pilots in each programme. Results: The pro-
ject delivered a general framework to implement the EE and BIA in the current 
processes of each of the three HTA programmes, allowing them to fit it into their 
timings and particular needs. According to this proposal, companies will submit 
their EE and BIAs of medicines in a similar way to what they currently do in single 
technology appraisals. The HTA programmes will assess the quality of the submitted 
information, and may ask for additional analyses when required. To date, the pilot 
on the therapeutic area of oncology has been completed (PHF-MHDA) whilst the 
other two are still ongoing. CAEIP also developed a set of formularies to be used by 
the companies when submitting the required information. Finally, the project was 
informative, as it highlighted the size the resources needed to implement this new 
process within the HTA programmes. cOnclusiOns: CatSalut continues with the 
deployment of EE and BIA as it believes both to be valuable when issuing recom-
mendations on the use and the therapeutic positioning of medicines within the 
Catalan health system.
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Objectives: ED processes between manufacturers, Regulators and HTAs was 
developed to improve quality of evidence and patient access to new medicines. 
SEED is a pilot project financed by the EC involving 14 EU HTAs. Sanofi engaged in 
HTA ED with or without Regulators in four different occasions. This is an overview 
of lessons learnt and suggestions for future improvements. MethOds: In order 
to collect quantitative and qualitative information on the execution of the pilots 
and to evaluate their impact on evidence generation, Sanofi conducted a cross 
sectional analysis amongst all departments involved in the four EDs through: - An 
ad hoc questionnaire probing quality of process, feedback and consensus across 
agencies - Candid meetings to refine response interpretation. Results: Approval 
requests, Briefing Book (BB) completions and clarifications were straightforward, 
although coordination was sometimes lacking. Process timelines seemed appro-
priate, nevertheless great variability in Sanofi’s efforts was observed depending on 
the therapeutic area and the type of advice sought. Teams were generally satisfied 
with the meetings, with good contributions from stakeholders and topics properly 
addressed. However, relevant items not reported in the BB could not be raised dur-
ing the discussion, not all attendees were involved in national negotiations and 
patients were not consistently represented. The quality of the feedback before, 
during and after the meeting was satisfactory. Yet, seeking consensus across HTAs 
was not observed, nor the final report always consistent with meeting discus-
sions. cOnclusiOns: Sanofi satisfaction about the ED experience was gener-
ally high, allowing to pressure test evidence development plans and scenarios, 
while garnering feedback on critical items from multiple countries. In order to 
truly improve evidence generation, some flexibility during the meeting should be 
allowed and consensus of opinion/advice achieved. All teams agreed on consulting 
in similar EDs in the future.
identified four products: trastuzumab emtansine, sofosbuvir, dolutegravir and 
riociguat. All had been assessed by CEESP and SMC; only one NICE assessment 
was published (sofosbuvir). For all products, except sofosbuvir, the type of model 
was different between agencies. All the published CEESP opinions reviewed cost-
effectiveness (CEA) and cost-utility analyses (CUA) whereas SMC and NICE only 
published CUA. Comparators and perspectives used were also different. For tras-
tuzumab emtansine, the Incremental Cost Effectiveness Ratio (ICER) published 
by SMC was 26.5% lower than the one published by CEESP. According to SMC 
guidance, riociguat and dolutegravir were dominant versus comparators, whereas 
CEESP published ICERs of 108 876 € /QALY and 16 526 € /QALY respectively. For 
sofosbuvir, most UK ICERs were higher than French ones. cOnclusiOns: Results 
confirm differences in recommendations and methodological requirements 
between the three agencies. Comparator heterogeneity due to different local 
practices appears to be a key factor leading to discrepancies in ICERs and cost-
effectiveness assessment. ICERs were higher in France than in the UK, possibly 
due to absence of established thresholds and no explicit impact on reimbursement 
decision.
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Objectives: Persistently stubborn infant mortality rates across the world have 
prompted the use of mobile technologies to assist in vaccine adherence. This sys-
tematic review attempts to assess the efficacy of a mobile phone technology in 
delivering timely infant immunization reminders and ensuring compliance and 
follow-up rates. MethOds: Studies were identified based on pre-specified criteria 
from two journals (BMJ and Lancet) and three databases (PUBMED, Google Scholar 
and Cochrane). The articles were screened for PICO (Population, Intervention, 
Control and Outcome) parameters and subsequently shortlisted when they included 
the desired target population, namely infants and mothers and used the methodol-
ogy of Randomized Controlled Trials (RCTs). Biases on account of dropouts, selection 
and blinding methods were taken into consideration. Risk ratios were analyzed for 
the review using a forest plot and bias graphs. Results: A total of 71 studies were 
identified based on results of which 3 duplicates were excluded. Of the 68, 25 were 
screened for PICO parameters and eventually of the 22 full-text articles reviewed. 
6 were RCTs and qualified as relevant for the Health Technology Assessment. The 
studies, published between 1996 and 2014, recorded the participation of 5999 infants 
and mothers across 5 clinic based interventions and 1 province-based intervention. 
A risk ratio of 0.67 indicates that the mobile-based intervention is 45% more effective 
than the control, suggesting the former to be a crucial measure to improve outcome 
measures such as timeliness of immunization and increased infant vaccine aware-
ness. cOnclusiOns: Our analysis suggests that the use of mobile technologies 
could marginally improve compliance in the intervention groups, even if they do not 
affect the overall immunization rates. The evidence also shows that incorporating 
this scheme into an existing health system requires a small investment that could 
potentially result in sizeable gains in reducing infant and neonatal mortality and 
morbidity, particularly in resource-limited settings.
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Objectives: There has been significant discussion on implementing a single Health 
Technology Assessment (HTA) process in Europe, in part because of the high level of 
variability among existing agencies. Agencies often disagree on the reimbursement 
decisions and on the economic and clinical conclusions. While disagreement on eco-
nomic evaluations and reimbursement decisions can be explained by different agency 
remits and healthcare budgets, the driving factors of and justifications for clinical var-
iability are currently unknown. This analysis examines drivers of clinical variability, 
specifically the clinical comparator, and uses case studies to explore instances where 
different comparators were used. MethOds: 198 reviews from NICE, SMC, PBAC, HAS 
and CADTH’s Common Drug Review were analyzed. Therapeutics were matched on 
indication, and the most recent review since 2007 for each agency was included if it 
was also reviewed by NICE. Agreement with NICE on the clinical comparator(s) used 
and on clinical evaluations were evaluated. Results: Agreement with NICE on the 
clinical comparator(s) ranged from 40% to 65%. Other agencies agreed with NICE’s 
clinical evaluations slightly more often when they also agreed on the comparator (54% 
vs. 45%); however, this trend was not statistically significant (p= .31). Case study evalu-
ations indicated that differences in country standards of care and agencies’ willing-
ness to accept comparators used in the clinical trials were common concerns in cases 
of comparator disagreement. cOnclusiOns: While there appears to be variability 
between NICE and the other agencies in comparator(s) evaluated, this does not appear 
to be a driving factor in clinical variability. Where differences in comparator(s) exist, 
a main theme identified was the differences in standards of care between countries. 
If agencies evaluate different comparators because of local standards of care, differ-
ent agencies would have to be willing to accept comparators not in line with their 
standard practices in order to implement a pan-European system.
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